Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04664218
Status:
COMPLETED
Last Update Posted:
2020-12-11
First Post:
2020-10-24
Brief Title:
Are You in a Poor Country HIPEC is Still in Reach
Sponsor:
Zagazig University
Organization:
Zagazig University
Study Overview
Official Title:
Are You in a Poor Country HIPEC is Still in Reach
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Peritoneal carcinomatosis PC is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin On occurrence PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy
On introduction of the new concept of combined optimal cytoreduction CRS followed by hyperthermic intraperitoneal chemotherapy HIPEC promising prognosis began to be shown
A major obstacle which may face application of HIPEC manoeuvre is the cost either of the machine or the disposable kit used in handling the chemotherapy heating it and delivering it to the patient hence we established our machine design with its disposable kits making it available for use in poor places
On introduction of the new concept of combined optimal cytoreduction CRS followed by hyperthermic intraperitoneal chemotherapy HIPEC promising prognosis began to be shown
A major obstacle which may face application of HIPEC manoeuvre is the cost either of the machine or the disposable kit used in handling the chemotherapy heating it and delivering it to the patient hence we established our machine design with its disposable kits making it available for use in poor places
Detailed Description:
As aforementioned the use of HIPEC technique offered a promising results in dealing with peritoneal carcinomatosis the high costs seems to be a considerable obstacle in some poor places so we inented a machine with considerably lower costs both in the machine composition and its disposable kit used for every patient we used it for six years in a trial to find any shortage obstacles or any technical therapeutic or financial drawbacks compared to the published data of the standard machines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None